Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - Should You Sell?

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR shares experienced a significant gap down, opening at $8.01 from a previous close of $8.53.
• The company reported $0.16 EPS for the last quarter, exceeding estimates, but revenue of $672.90 million was below expectations.
• Despite recent performance, analysts anticipate Shionogi will report 0.66 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report)'s share price gapped down before the market opened on Wednesday . The stock had previously closed at $8.53, but opened at $8.01. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.01, with a volume of 627 shares.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The company has a fifty day moving average price of $8.79 and a two-hundred day moving average price of $8.42. The company has a current ratio of 6.63, a quick ratio of 6.13 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. The firm had revenue of $672.90 million for the quarter, compared to analysts' expectations of $719.55 million. As a group, analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.